Ivermectin with immunotherapy for advanced solid tumors
Part of Cancer clinical trials.
This trial tests if adding ivermectin, a common anti-parasitic drug, to standard immunotherapy (checkpoint inhibitors) can help fight solid tumors. You may be eligible if you are already on immunotherapy for at least 21 days and have a stable or manageable cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a solid tumor and have been on an immunotherapy drug (checkpoint inhibitor) for at least 3 weeks.
- You are 18 years or older.
- You are able to swallow pills and do not have a major stomach or bowel problem that affects absorption.
- Your general health is good enough to carry out daily activities (ECOG score 0-2).
- You are willing to avoid pregnancy or fathering children during the study and for 4 weeks after.
- You have not taken ivermectin recently unless you stop for 2 weeks before starting the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether ivermectin, given together with immunotherapy (balstilimab or pembrolizumab), can help treat metastatic triple-negative breast cancer. It mainly looks at safety first, and may also explore how well the treatment works for people whose cancer has spread.
This Phase 1 trial tests a new drug called IUAb190708 designed to help your immune system fight advanced or recurrent solid cancers. The study will evaluate its safety, how your body handles it, and whether it works against your tumor.
This trial tests whether adding mistletoe extract (Iscador) to standard immunotherapy can make the treatment safer and boost the immune system's response against advanced solid tumors (excluding skin cancer). If you are already receiving or about to start a checkpoint inhibitor, this study may help understand if the combination works better.
This trial tests a new immunotherapy drug called ivonescimab given together with standard chemotherapy for advanced stomach cancer. It may help your immune system fight the cancer more effectively.
This trial tests an experimental drug called IPN01203 for people with advanced solid tumors that have grown after prior immunotherapy. The goal is to see if the drug is safe and can shrink tumors.
This study tests a new immune cell therapy (EVM16) given alone or with another drug (tislelizumab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination can help shrink tumors or slow their growth.
Hear when a new Solid Tumor, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.